Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium-dependent glucose cotransporter 2 (SGLT2) is a protein encoded by the SLC5A2 gene. It is the major cotransporter involved in glucose reabsorption in the kidney, specifically located in the early proximal tubule (S1 and S2 segments). It is responsible for reabsorbing approximately 80-90% (or up to 97%) of the glucose filtered by the kidney glomerulus. SGLT2 is a symporter belonging to the SLC5 family, utilizing the energy from the sodium gradient created by the Na+/K+ ATPase to transport glucose into the cell, even against its concentration gradient. The protein consists of approximately 670 amino acids organized in 14 transmembrane helices. While predominantly expressed in the renal cortex, it has also been found in other tissues including mammary glands, testis, liver, lungs, intestines, skeletal muscles, spleen, and cerebellum.
SGLT2 inhibitors prevent the kidneys' reuptake of glucose from the glomerular filtrate by inhibiting the SGLT2 transporter in the proximal tubule. This leads to increased urinary glucose excretion and consequently lowers blood glucose levels. This mechanism is insulin-independent.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium-dependent glucose cotransporter 2 (SGLT2).